• linkedin
  • Increase Font
  • Sharebar

    These novel strategies may change DME treatment paradigm

    By Michelle Dalton, ELS; Reviewed by Pravin U. Dugel, MD

    There is no denying that the anti-vascular endothelial growth factor A (anti-VEGF-A) monotherapy has “absolutely revolutionized our treatment of diabetic macular edema (DME).” However, there is a subset of patients in whom the anti-VEGFs are not an optimal treatment, according to Pravin U. Dugel, MD.

    That subset of patients “with resistant or persistent disease” form the impetus for new treatment strategies, including next-generation anti-VEGF-A and new classes of drugs, said Dr. Dugel, managing partner, Retinal Consultants of Arizona, Phoenix, and clinical professor, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles.

    Here is a list of potential treatment candidates that may lead that paradigm shift:


    Brolucizumab (Alcon Laboratories/Novartis) represents “the smallest active unit of antibody that allows for concentrated molar dosing: 22 times that of ranibizumab (Lucentis, Genentech) and more than 11 times that of aflibercept (Eylea, Regeneron Pharmaceuticals),” Dr. Dugel said.

    Two phase III studies compared brolucizumab to aflibercept in patients with neovascular age-related macular degeneration (AMD), with non-inferiority found for the primary endpoint and superiority in key retinal health outcomes.

    “DME trials with brolucizumab are currently being planned,” Dr. Dugel said.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';